Adamas Pharmaceuticals, Inc.
(NASDAQ GM: ADMS)
Rigrodsky Law, P.A. is investigating Adamas Pharmaceuticals, Inc. (“Adamas”) regarding possible breaches of fiduciary duties and other violations of law related to Adamas’ agreement to be acquired by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, Adamas’ shareholders will receive $8.10 in cash and two non-tradeable contingent value rights collectively worth up to $1.00 per share.